Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03197467 | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer(NEOMUN) | completed | Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04735068 | Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | completed | Phase 2 | 9 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05298176 | Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors(COMBINATION) | completed | Phase 2 | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03631784 | A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)(KEYNOTE-799) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 25, 2025 | clinicaltrials |
| NCT02582125 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 53 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03526887 | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC(Replay) | completed | Phase 2 | 73 | Spanish Lung Cancer GroupOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04003246 | Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05137067 | A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. | completed | Phase 2 | 90 | Optimal Health ResearchOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment(SPRINT) | completed | Phase 1 / Phase 2 | 126 | Karyopharm Therapeutics IncINDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05058560 | Tislelizumab in Addition to BACE in Patients with NSCLC | completed | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04172506 | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 65 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05505825 | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AkesoINDUSTRY | 2 | Mar 12, 2025 | clinicaltrials |
| NCT02535338 | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04880863 | NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC(NT-NAP-102-1) | completed | Phase 2 | 38 | NeoTX Therapeutics Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT03543683 | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | completed | Phase 2 | 115 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02424617 | A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | BerGenBio ASAINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04997382 | Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC(CLASSIC5) | completed | Phase 2 | 112 | Hunan Province Tumor HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05000684 | Study of JS004 Combined With Toripalimab for Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 67 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02597946 | Afatinib in NSCLC With HER2 Mutation | completed | Phase 2 | 18 | Boehringer IngelheimINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03669523 | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)(DENIVOS) | completed | Phase 2 | 82 | Centre Hospitalier Annecy GenevoisOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03414814 | Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation | completed | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02733159 | Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2(PePS2) | completed | Phase 2 | 62 | University of BirminghamOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04263051 | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer(Optim-UCPVax) | completed | Phase 2 | 60 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02841579 | Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M(AZENT) | completed | Phase 2 | 22 | MedSIROTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05309629 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 40 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT04249362 | Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy(DUART) | completed | Phase 2 | 102 | AstraZenecaINDUSTRY | 6 | Jan 10, 2025 | clinicaltrials |
| NCT02818426 | Universal Cancer Peptide-based Vaccination in Metastatic NSCLC(UCPVax) | completed | Phase 1 / Phase 2 | 82 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT03262779 | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | completed | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05146219 | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | completed | Phase 2 | 29 | TYK Medicines, IncINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03043599 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03232138 | Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers | completed | Phase 2 | 43 | Jian-Min Yuan, MDOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT01789099 | A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.(UV1-hTERT2012L) | completed | Phase 1 / Phase 2 | 18 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT04946019 | MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT02175017 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 104 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04691388 | A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor | completed | Phase 2 | 29 | Zhejiang Cancer HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03081689 | Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients | completed | Phase 2 | 46 | Spanish Lung Cancer GroupOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05807893 | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases(SUPER BRAIN) | completed | Phase 2 / Phase 3 | 40 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT05048082 | A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies | completed | Phase 2 | 24 | OncoNano Medicine, Inc.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05898763 | TEIPP Immunotherapy in Patients With NSCLC(TEIPP) | completed | Phase 1 / Phase 2 | 26 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02094261 | Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours(AURA2) | completed | Phase 2 | 210 | AstraZenecaINDUSTRY | 8 | Nov 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 4, 2025source: clinicaltrials